Buccal Versus Vaginal Misoprostol for Third Trimester Induction of Labor
Approximately 22% of term pregnancies are induced. Misoprostol, a prostaglandin E1 analogue, is a widely accepted induction agent, that has been proven safe and effective for induction of labor. It stimulates both cervical ripening and uterine contractions, thus making it an ideal induction agent for unfavorable cervices. Research has examined the pharmacokinetics of different administration routes and effects on uterine contractility, side effects, and safety. Vaginal misoprostol has been shown to be superior over oral administration however patients often prefer a more tolerable route. Buccal administration has already been shown to be as effective as vaginal misoprostol for cervical ripening and induction in both first trimester and second trimester abortions. There is minimal research comparing buccal versus vaginal for third trimester induction of labor. The investigators study is a prospective, double blinded, randomized control trial comparing vaginal misoprostol and buccal misoprostol in equal dosages of 25 mcg. The investigators seek to answer the question whether buccal misoprostol is as effective as vaginal misoprostol for third trimester induction of labor.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Buccal Versus Vaginal Misoprostol for the Third Trimester Induction of Labor|
- Efficacy of buccal misoprostol versus vaginal misoprostol for third trimester induction of labor [ Time Frame: Until delivery (up to 72 hrs) ] [ Designated as safety issue: No ]The main outcome variable is vaginal delivery within 24 hours of induction.
- Patient satisfaction with buccal versus vaginal misoprostol administration. [ Time Frame: Until delivery (up to 72hrs) ] [ Designated as safety issue: No ]Gastrointestinal side effects Patient preferred route of administration Patients will be followed for the duration of their labor(usually up to 72hrs). The satisfaction survey will be conducted after delivery but will evaluate side effects that they recollect in labor
- Efficacy of buccal misoprostol versus vaginal misoprostol for third trimester induction of labor [ Time Frame: Until delivery (up to 72 hrs) ] [ Designated as safety issue: No ]Induction to delivery time, Induction to active labor time, Duration of labor, Number of misoprostol doses needed, Need for augmentation with pitocin, Cesarean section secondary to fetal distress, Cesarean section secondary to failed induction of labor, Chorioamnionitis, non reassuring fetal status. Patients will be followed for the duration of their labor(usually up to 72hrs)
|Study Start Date:||July 2011|
|Estimated Study Completion Date:||December 2013|
|Estimated Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
|Experimental: Buccal misoprostol+placebo vaginal pill||
Drug: Buccal Misoprostol
Buccal rather than Vaginal misoprostol for induction of labor
Other Name: Cytotec
|Active Comparator: Vaginal Misoprostol+placebo buccal pill||
Drug: Vaginal misoprostol
Vaginal rather than buccal misoprostol for induction of labor
Other Name: Cytotec
Hide Detailed Description
Design Overview This will be a prospective, double blind, randomized, placebo-controlled trial comparing buccal versus vaginal misoprostol in equal doses (25 mcg every 4 hours). Each participant will receive one buccal and one vaginal tablet, only one containing misoprostol. The administration will be repeated every four hours if contractions are inadequate (frequency less than every 5 minutes) until the cervix is favorable, spontaneous rupture of membranes occurs, or the patient is in active labor. Patient will be continued on intermittent fetal heart monitoring 1 hour after administration. Prior to discharge women in the study will be asked to complete a questionnaire as to their preferences of route of administration and side effects.
Recruitment, Consenting, and Confirming Eligibility: Women with obstetric, medical, or psychosocial indications of induction of labor at UCLA Ronald Reagan Medical Center will be evaluated for participation. Those who meet eligibility criteria will be invited to participate. The subject will be counseled about the study, and if interested, will undergo the consent process. Each potential subject will receive a thorough overview of the study protocol and will review the consent form with study staff. All questions will be answered. The subject will be advised that a decision not to participate in the study will not affect the quality or availability of medical services she will receive at the hospital. She will also be advised that she can stop participating in the study at any time, for any reason, and that this will not impact the services she receives. If the subject elects to participate, two copies of the consent will be signed by the subject and research staff. A signed consent, along with a copy of the Experimental Subjects Bill of Rights, will be given to the subject. The other consent will be filed in a locked file cabinet.
A general medical and gynecological history and physical will be done as is standard of care. Routine obstetric labs and any other medically indicated labs will be sent as is standard of care. Patients will undergo a non-stress test and uterine contraction monitoring prior to induction of labor. Obstetrical ultrasound will be reviewed or performed if indicated per the physician. Assessment of the cervix and Bishop score, pelvis, fetal size, and presentation will be performed. An unfavorable cervix is defined as Bishop score of 6 or less (ACOG). Women with ruptured membranes will not be able to participate. Gestational age will be determined on the basis of last menstrual period, confirmed by earliest ultrasound, or a corrected estimated date of confinement by the earliest ultrasound.
Misoprostol Administration/ Evaluation: The subject will be randomized to either of two groups. Each participant will receive both a vaginal and buccal tablet, with one tablet containing misoprostol. Subjects will be instructed by a nurse regarding buccal placement and to swallow any residue remaining after 20 minutes.
Intravaginal administration of pill will be performed by a resident Physician or midwife. The subject will remain recumbent for at least 30 minutes. The subject will undergo fetal heart rate (FHR) and uterine contraction monitoring for at least 1 hour after misoprostol administration. The subject may undergo further FHR and uterine contraction monitoring per physician discretion. If the subject does not have adequate uterine contractions (uterine contraction occurring at least every 5 minutes), the same dosage and route of administration regimen will be repeated to 6 maximum dosage (maximum of 150mcg). Cervical assessment of Bishop score will be performed with each treatment during vaginal administration.
Treatment will continue until spontaneous rupture of membranes, active labor, or favorable cervix (Bishop >6). Augmentation of labor using pitocin may start after 4 hours of last misoprostol dose according to routine protocol. Amniotomy may be performed at the discretion of the managing obstetrician. If labor is not achieved after receiving 150mcg of misoprostol, it will be categorized as a failed induction. At this time, the subject may be offered oxytocin induction, foley bulb mechanical dilation, or cesarean section, according to the fetal and participant condition. Terbutaline 0.25mg subcutaneous may be given for tachysystole (5 uterine contractions in 10 minutes) with FHR changes or FHR category II-III changes (minimal variability, prolonged deceleration, repetitive variables, sinusoidal pattern, repetitive late deceleration) that are not responsive to resuscitative measures ( oxygen supplementation, side positioning, intravenous fluids) according to physician's discretion.
- Follow up: A short survey questionnaire assessing gastrointestinal side effects, experiences, and preferences of route of administration will be given prior to discharge.
|Contact: Linh Tran, MD||310 825 6301||LinhTran@mednet.ucla.edu|
|Contact: Amy Shah, MD||310 825 6301||AShah@mednet.ucla.edu|
|United States, California|
|Ronald Reagan UCLA Medical Center||Recruiting|
|Los Angeles, California, United States, 90095|
|Sub-Investigator: Linh Tran, MD|
|Principal Investigator:||Ram Parvataneni, MD||Assistant Clinical Professor|